Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
However, only 24% of people with hepatocellular carcinoma received direct-acting antiviral therapy.
Nearly 70% of prior HBV vaccine nonresponders produced adequate antibodies after successful HCV treatment.
Offering hepatitis C treatment at the point of diagnosis streamlines care, saving both time and money.
Hepatocellular carcinoma among people with HCV fell after the debut of direct-acting antivirals, but cases are rising for other groups.
Hepatitis C prevalence was higher among people with unstable housing and those who injected drugs every day.
Only 20% of people covered by Medicaid received treatment within six months of their HCV diagnosis.
Modern antivirals can cure 95% of people with HCV, lowering the risk of cirrhosis, liver cancer and liver failure.
Older people, men and people living in poverty and lacking private insurance were more likely to have active HCV infection.
The CDC estimates that 21% of people living with HIV also have hepatitis C virus.
Hepatitis A and B declined in 2021, but new hepatitis C cases have doubled since 2014.
Drug-related mortality, including overdose, was the leading cause of death.
About 40% of people worldwide are not aware that viral hepatitis is a leading cause of liver cancer.
Viral hepatitis could kill more people than malaria, tuberculosis and HIV combined if trends continue.
A “jarringly low” proportion of people with HCV have been tested, treated and cured.
The burden of viral and nonviral liver disease remains high even in the setting of hepatitis C microelimination.
People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.